On March 21, 2019, Forbes spotlighted AFAR experts Nir Barzilai, MD, and Jim Mellon in an article exploring biotech opportunities to extend healthspan, including the AFAR-managed TAME (Targeting Aging with Metformin) Trial.
Dr. Barzilai is AFAR’s Deputy Scientific Director, a multiple grantee, and Director of the Nathan Shock Center at Einstein Medical College, for which AFAR serves as the coordinating center.
Mr. Mellon is an AFAR Board member and recipient of our 2018 George E. and Mary J. Doty Award recipient.
The article also mentions research and interventions by 2015 Irving S. Wright Award winner Leonard Guarente, PhD.
Read “Opportunities For Biotech Companies May Exist In The Anti-Aging Market” here.
